foxo4-dri senolytic peptide research UK | Buy FOXO4-DRI (Proxofim) - Senolytic
Description
Fruhbeck G, Kiortsis DN, Catalan V
Hung SH, Xirasagar S, Cheng YF, Kuo NW, Lin HC
(Peptide Sciences) Oncology & adjunctive therapy Interestingly, since senescent cells often accumulate in tissues post-chemotherapy and may contribute to relapse or fibrosis, FOXO4-DRI might serve as adjuncts in oncology (preclinical) by clearing therapy-induced senescent cells
In a Swedish cohort study,16 there was a higher risk of a first invasive melanoma in patients with rheumatoid arthritis receiving TNF alpha inhibitors than in those not treated with them
